Rituximab

Drug Profile

Rituximab

Alternative Names: IDEC-102; IDEC-C2B8; MabThera; R 105; RG 105; Rituxan; Rituximab-EU; RO-452294

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Halozyme Therapeutics; Hoosier Cancer Research Network; Oregon Health & Science University; Roche; SCRI Development Innovations; Takeda Oncology; University of Texas M. D. Anderson Cancer Center; University of Tours; Zenyaku Kogyo
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoproliferative disorders; Microscopic polyangiitis; Nephrotic syndrome; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis
  • Preregistration Haematological malignancies
  • Phase III Mantle-cell lymphoma; Pemphigus vulgaris; Transplant rejection
  • Phase II/III Neuromyelitis optica
  • Phase II B cell lymphoma
  • No development reported Multiple sclerosis; Ocular inflammation; Primary biliary cirrhosis; Scleritis; Sjogren's syndrome; Ulcerative colitis
  • Discontinued Dermatomyositis; Graft-versus-host disease; Immune thrombocytopenic purpura; Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 01 Feb 2017 Genetech terminates a phase III trial in Nephrotic syndrome (In infants, In children, In adolescents) in USA as the sponsor milestones and financing requirements could not be met (NCT02390362)
  • 13 Dec 2016 Launched for Diffuse large B cell lymphoma (Combination therapy, First-line therapy) in Canada (SC)
  • 13 Dec 2016 Launched for Follicular lymphoma (Combination therapy, First-line therapy, Metastatic disease, Late-stage disease) in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top